Cambridge biotech Sarepta tops $11B market cap on gene therapy data
Sarepta Therapeutics on Tuesday released promising data from a small, early-stage trial of its experimental gene therapy treatment for Duchenne muscular dystrophy, showing that the drug significantly boosted an important muscle protein in three boys with the disease.
Shares of Sarepta (Nasdaq: SRPT) soared Tuesday morning on the news, propelling its market cap from $6.9 billion to more than $11 billion briefly, before dropping back to $10.6 billion as of 11:15 a.m. The stock increase of 54 percent…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Max Stendahl Source Type: news
More News: Biotechnology | Boys | Gene Therapy | Genetics | Health Management | Muscular Dystrophy | Pharmaceuticals | Reflex Sympathetic Dystrophy